{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:29:34Z","timestamp":1785871774049,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patient-derived in vitro systems are powerful preclinical models that replicate key features of human tumors and enable investigation of cancer biology and drug response. They are particularly promising for pancreatic cancer research. We examined whether culture dimensionality and basement membrane extract (BME) composition affect establishment rates, morphology, proliferation, marker expression, and drug response in patient-derived models of pancreatic ductal adenocarcinoma (PDAC). From 12 PDAC samples, matched two-dimensional primary cell lines (PDCLs) and three-dimensional organoids were established in Cultrex (PDOCs) and Matrigel (PDOMs). PDCLs formed monolayers, while PDOCs and PDOMs developed cystic or dense organoids, independent of BME type. Immunohistochemistry showed no differences in key diagnostic markers between culture systems, and Ki-67 levels were consistently higher in vitro compared to original tumors. Pharmacological testing with five standard chemotherapeutics revealed no significant differences in drug response between dimensionalities or BMEs, although 3D models were detected to be slightly more chemoresistant. In two patients treated with gemcitabine monotherapy, in vitro therapy response correlated with clinical relapse. Our findings indicate that while drug responses are largely patient-specific and independent of dimensionality and matrix composition, 3D models more realistically recapitulate tumor architecture and phenotypes, supporting their value for translational PDAC research.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical approval was requested and granted by the ethics committee of the Charit\u00e9\u00a0Universit\u00e4tsmedizin Berlin (EA1\/157\/21) on 26th May 2021.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-47856-1","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:06:04Z","timestamp":1776150364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models"],"prefix":"10.1038","volume":"16","author":[{"given":"Florian","family":"Doelvers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea P.","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Janik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hilfenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matth\u00e4us","family":"Felsenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Lerchbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"J\u00fcrgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Duwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C. M.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"47856_CR1","unstructured":"Zentrum f\u00fcr Krebsregisterdaten und Gesellschaft der Epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland. (2021)."},{"key":"47856_CR2","doi-asserted-by":"publisher","unstructured":"Wood, L. D., Canto, M. I., Jaffee, E. M. & Simeone, D. M. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology 163, 386\u2013402 e381 (2022). https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056","DOI":"10.1053\/j.gastro.2022.03.056"},{"key":"47856_CR3","unstructured":"Leitlinienprogramm Onkologie, D. K. AWMF). S3-Leitlinie Exokrines Pankreaskarzinom, Langversion 2.0, 2021, AWMF Registernummer: 032-010OL. (2021). https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/pankreaskarzinom\/"},{"key":"47856_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070991","author":"L Moletta","year":"2019","unstructured":"Moletta, L. et al. Surgery for recurrent pancreatic cancer: Is it effective?. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11070991 (2019).","journal-title":"Cancers (Basel)"},{"key":"47856_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ijc.2910150505","volume":"15","author":"M Lieber","year":"1975","unstructured":"Lieber, M., Mazzetta, J., Nelson-Rees, W., Kaplan, M. & Todaro, G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int. J. Cancer. 15, 741\u2013747. https:\/\/doi.org\/10.1002\/ijc.2910150505 (1975).","journal-title":"Int. J. Cancer"},{"key":"47856_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006676-200203000-00001","volume":"24","author":"AB Ulrich","year":"2002","unstructured":"Ulrich, A. B., Schmied, B. M., Standop, J., Schneider, M. B. & Pour, P. M. Pancreatic cell lines: A review. Pancreas 24, 111\u2013120. https:\/\/doi.org\/10.1097\/00006676-200203000-00001 (2002).","journal-title":"Pancreas"},{"key":"47856_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gutjnl-2016-313133","volume":"67","author":"ES Knudsen","year":"2018","unstructured":"Knudsen, E. S. et al. Pancreatic cancer cell lines as patient-derived avatars: Genetic characterisation and functional utility. Gut 67, 508\u2013520. https:\/\/doi.org\/10.1136\/gutjnl-2016-313133 (2018).","journal-title":"Gut"},{"key":"47856_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212200","author":"O Habanjar","year":"2021","unstructured":"Habanjar, O., Diab-Assaf, M., Caldefie-Chezet, F. & Delort, L. 3D cell culture systems: Tumor application, advantages, and disadvantages.. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms222212200 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"47856_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0416-8","volume":"17","author":"MJ Kim","year":"2017","unstructured":"Kim, M. J. et al. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Cancer Cell Int 17, 47. https:\/\/doi.org\/10.1186\/s12935-017-0416-8 (2017).","journal-title":"Cancer Cell Int"},{"key":"47856_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114876","volume":"14","author":"K Peschke","year":"2022","unstructured":"Peschke, K. et al. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol. Med. 14, e14876. https:\/\/doi.org\/10.15252\/emmm.202114876 (2022).","journal-title":"EMBO Mol. Med."},{"key":"47856_CR11","doi-asserted-by":"publisher","unstructured":"Kim, H. et al. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma (with video). Gastrointest Endosc 100, 85\u201396 e89 (2024). https:\/\/doi.org\/10.1016\/j.gie.2024.02.021","DOI":"10.1016\/j.gie.2024.02.021"},{"key":"47856_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.612271","volume":"12","author":"S Liot","year":"2021","unstructured":"Liot, S. et al. Stroma involvement in pancreatic ductal adenocarcinoma: An overview focusing on extracellular matrix proteins. Front. Immunol. 12, 612271. https:\/\/doi.org\/10.3389\/fimmu.2021.612271 (2021).","journal-title":"Front. Immunol."},{"key":"47856_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/physiol.00036.2016","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval, K. et al. Modeling physiological events in 2D vs. 3D cell culture. Physiology (Bethesda) 32, 266\u2013277. https:\/\/doi.org\/10.1152\/physiol.00036.2016 (2017).","journal-title":"Physiology (Bethesda)"},{"key":"47856_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112539","author":"AK Beutel","year":"2021","unstructured":"Beutel, A. K. et al. A prospective feasibility trial to challenge patient-derived pancreatic cancer organoids in predicting treatment response.. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13112539 (2021).","journal-title":"Cancers (Basel)"},{"key":"47856_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010227","author":"M Amrutkar","year":"2020","unstructured":"Amrutkar, M. et al. Establishment and characterization of paired primary cultures of human pancreatic cancer cells and stellate cells derived from the same tumor.. Cells https:\/\/doi.org\/10.3390\/cells9010227 (2020).","journal-title":"Cells"},{"key":"47856_CR16","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.3892\/ol.2017.7134","volume":"14","author":"D Lv","year":"2017","unstructured":"Lv, D., Hu, Z., Lu, L., Lu, H. & Xu, X. Three-dimensional cell culture: A powerful tool in tumor research and drug discovery. Oncol. Lett. 14, 6999\u20137010. https:\/\/doi.org\/10.3892\/ol.2017.7134 (2017).","journal-title":"Oncol. Lett."},{"key":"47856_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724\u20131743. https:\/\/doi.org\/10.1038\/nprot.2016.097 (2016).","journal-title":"Nat. Protoc."},{"key":"47856_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06929-8","volume":"20","author":"L Ehlen","year":"2020","unstructured":"Ehlen, L. et al. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer 20, 417. https:\/\/doi.org\/10.1186\/s12885-020-06929-8 (2020).","journal-title":"BMC Cancer"},{"key":"47856_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.gie.2024.04.012","volume":"100","author":"SE Grutzmeier","year":"2024","unstructured":"Grutzmeier, S. E. et al. EUS-guided biopsies versus surgical specimens for establishing patient-derived pancreatic cancer organoids: A systematic review and meta-analysis. Gastrointest. Endosc. 100, 750\u2013755. https:\/\/doi.org\/10.1016\/j.gie.2024.04.012 (2024).","journal-title":"Gastrointest. Endosc."},{"key":"47856_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.26.525757","author":"J Lumibao","year":"2023","unstructured":"Lumibao, J. et al. (ed, C.) The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. bioRxiv https:\/\/doi.org\/10.1101\/2023.01.26.525757 (2023).","journal-title":"bioRxiv"},{"key":"47856_CR21","unstructured":"FDA, Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs (2025), accessed June 21, 2025, https:\/\/ www. fda. gov\/news-events\/press -annou nceme nts\/ fda-annou nces-plan-phase -out-anima l-testi ng-requi remen t-monoc lonal -antib odies-and-other-drugs"},{"key":"47856_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3109\/09553000903258897","volume":"85","author":"SA Schmid","year":"2009","unstructured":"Schmid, S. A., Dietrich, A., Schulte, S., Gaumann, A. & Kunz-Schughart, L. A. Fibroblastic reaction and vascular maturation in human colon cancers. Int. J. Radiat. Biol. 85, 1013\u20131025. https:\/\/doi.org\/10.3109\/09553000903258897 (2009).","journal-title":"Int. J. Radiat. Biol."},{"key":"47856_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71490","volume":"15","author":"K Wansch","year":"2026","unstructured":"Wansch, K. et al. Identifying factors of organoid establishment in pancreatic cancer: A prospective observational study. Cancer Med. 15, e71490. https:\/\/doi.org\/10.1002\/cam4.71490 (2026).","journal-title":"Cancer Med."},{"key":"47856_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02374-y","volume":"24","author":"JS Kim","year":"2025","unstructured":"Kim, J. S. et al. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer. Mol. Cancer 24, 162. https:\/\/doi.org\/10.1186\/s12943-025-02374-y (2025).","journal-title":"Mol. Cancer"},{"key":"47856_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41551-024-01273-9","volume":"9","author":"A Papargyriou","year":"2025","unstructured":"Papargyriou, A. et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat. Biomed. Eng. 9, 836\u2013864. https:\/\/doi.org\/10.1038\/s41551-024-01273-9 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"47856_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48347-2","volume":"9","author":"C Magliaro","year":"2019","unstructured":"Magliaro, C., Rinaldo, A. & Ahluwalia, A. Allometric scaling of physiologically-relevant organoids. Sci. Rep. 9, 11890. https:\/\/doi.org\/10.1038\/s41598-019-48347-2 (2019).","journal-title":"Sci. Rep."},{"key":"47856_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31376-3","volume":"13","author":"ME Monberg","year":"2022","unstructured":"Monberg, M. E. et al. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. Nat. Commun. 13, 3652. https:\/\/doi.org\/10.1038\/s41467-022-31376-3 (2022).","journal-title":"Nat. Commun."},{"key":"47856_CR28","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E23-02-0075","volume":"34","author":"OH Usman","year":"2023","unstructured":"Usman, O. H. et al. Differential modulation of cellular phenotype and drug sensitivity by extracellular matrix proteins in primary and metastatic pancreatic cancer cells. Mol. Biol. Cell 34, ar130. https:\/\/doi.org\/10.1091\/mbc.E23-02-0075 (2023).","journal-title":"Mol. Biol. Cell"},{"key":"47856_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86028-1","volume":"11","author":"F Minami","year":"2021","unstructured":"Minami, F. et al. Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures. Sci. Rep. 11, 6775. https:\/\/doi.org\/10.1038\/s41598-021-86028-1 (2021).","journal-title":"Sci. Rep."},{"key":"47856_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.humpath.2021.05.012","volume":"115","author":"A Menz","year":"2021","unstructured":"Menz, A. et al. Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: A tissue microarray study of 13,172 tumors. Hum. Pathol. 115, 19\u201336. https:\/\/doi.org\/10.1016\/j.humpath.2021.05.012 (2021).","journal-title":"Hum. Pathol."},{"key":"47856_CR31","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-22-1272","volume":"28","author":"GM O'Kane","year":"2022","unstructured":"O\u2019Kane, G. M. et al. Correction: GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 28, 2715. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1272 (2022).","journal-title":"Clin. Cancer Res."},{"key":"47856_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086853","volume":"9","author":"W Xiao","year":"2014","unstructured":"Xiao, W., Hong, H., Awadallah, A., Zhou, L. & Xin, W. Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis. PLoS One 9, e86853. https:\/\/doi.org\/10.1371\/journal.pone.0086853 (2014).","journal-title":"PLoS One"},{"key":"47856_CR33","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre, T. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33, 4176\u20134187. https:\/\/doi.org\/10.1200\/JCO.2015.63.4238 (2015).","journal-title":"J. Clin. Oncol."},{"key":"47856_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat. Commun. 16, 5919. https:\/\/doi.org\/10.1038\/s41467-025-60808-z (2025).","journal-title":"Nat. Commun."},{"key":"47856_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158515","author":"G Girolimetti","year":"2024","unstructured":"Girolimetti, G. et al. Characterization of chemoresistance in pancreatic cancer: A look at MDR-1 polymorphisms and expression in cancer cells and patients. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25158515 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"47856_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L de Sousa Cavalcante","year":"2014","unstructured":"de Sousa Cavalcante, L. & Monteiro, G. Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741, 8\u201316. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.041 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"47856_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","volume":"17","author":"W Muriithi","year":"2020","unstructured":"Muriithi, W. et al. ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol. Med. 17, 253\u2013269. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0284 (2020).","journal-title":"Cancer Biol. Med."},{"key":"47856_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2 (2017).","journal-title":"Genome Med."},{"key":"47856_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/path.6439","volume":"267","author":"Z Leoni","year":"2025","unstructured":"Leoni, Z. et al. Mucinous cystic neoplasms of the pancreas and liver share a similar DNA methylation profile with mucinous ovarian tumors. J. Pathol. 267, 10\u201324. https:\/\/doi.org\/10.1002\/path.6439 (2025).","journal-title":"J. Pathol."},{"key":"47856_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527. https:\/\/doi.org\/10.1038\/nmeth.3853 (2016).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47856-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:47:10Z","timestamp":1779194830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47856"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47856-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all enrolled subjects as part of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent\u00a0<!--Emphasis Type='Bold' removed-->statement"}}],"article-number":"12346"}}